454482-12-3

Basic information

• Product Name: 4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE
• Synonyms: 4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE;4-(4-Methylpiperidin-1-yl)aniline;4-(1-Methyl-4-piperidyl)phenylamine;4-(4-Aminophenyl)-1-methylpiperidine;Benzenamine, 4-(1-methyl-4-piperidinyl)-
• CAS NO: 454482-12-3
• Molecular Formula: C12H18N2
• Molecular Weight: 190.28
• Mol File: 454482-12-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 348.5°C at 760 mmHg
• Flash Point: 144.5°C
• Appearance: /
• Density: 1.034
• Vapor Pressure: 5.01E-05mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 8.90±0.20(Predicted)
• CAS DataBase Reference: 4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE(454482-12-3)
• EPA Substance Registry System: 4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE(454482-12-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 454482-12-3(Hazardous Substances Data)

Usage

Uses

4-(1-Methylpiperidin-4-yl)aniline is used for preparation of pyridopyrimidinones as antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors and pharmacokinetics.

InChI:InChI=1/C12H18N2/c1-10-6-8-14(9-7-10)12-4-2-11(13)3-5-12/h2-5,10H,6-9,13H2,1H3

Upstream product

• 46712-55-4 1-methyl-4-(4-nitrophenyl)pyridinium 

Downstream Products

• 1443042-73-6 6-tert-butyl-8-fluoro-2-(2-hydroxymethyl-3-{8-[4-(1-methyl-piperidin-4-yl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-2H-phthalazin-1-one 
• 1443042-72-5 acetic acid 2-(6-tert-butyl-8-fluoro-1-oxo-1H-phthalazin-2-yl)-6-{8-[4-(1-methyl-piperidin-4-yl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-benzyl ester 
• 1443042-71-4 (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-[4-(1-methyl-piperidin-4-yl)-phenyl]-amine 
• 1403885-93-7 (8-methoxy-2H-pyrazolo[3,4-c]quinolin-4-yl)-[4-(1-methyl-piperidin-4-yl)-phenyl]-amine 
• 700807-54-1 N₃-[4-(1-methyl-piperidin-4-yl)-phenyl]-1-pyridin-2-yl-1H-[1,2,4]triazole-3,5-diamine 

Relevant articles and documents

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.